NCT07494201Recruiting
MIMICC Study in Patients With Colorectal Cancer
Analysis of MicroRNA Expression and Microbiome Composition During the Diagnostic-Therapeutic Pathway of Patients With Colorectal Carcinoma
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
This multicenter prospective interventional study will evaluate stool and saliva microRNA expression and microbiome composition in patients with histologically confirmed colon or rectal cancer during key phases of the diagnostic and therapeutic pathway. The study aims to confirm and refine molecular signatures associated with colorectal cancer, assess the diagnostic and prognostic potential of salivary biomarkers, and characterize dynamic molecular changes during treatment and follow-up
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 2500 (estimated)
- First submitted
- 20 Mar 2026
- Start date
- 15 Sept 2025
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Fondazione del Piemonte per l'Oncologia
- Diseases
- Colorectal cancer
- NCT number
- NCT07494201
What you commit to
- Study type: Interventional
- Planned participants: 2500
- From 15 Sept 2025 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of immunosuppressive or immunomodulatory drugs within the previous 6 months
- Current or previous diagnosis of other solid or hematologic malignancies
Other
- Tis/T1 lesions or lesions almost completely resected by endoscopic polypectomy/EMR/ESD
- Inability or refusal to provide informed consent
- Inability or refusal to be followed at the study institution/network
Who the study is looking for
- Histologically confirmed colon or rectal cancer on endoscopic biopsy
- Any T stage, any N stage, M0-M1, candidate for surgical intervention
- Colon tumors with indication for surgical resection with curative intent, including right hemicolectomy, left hemicolectomy, transverse colon resection, colectomy, or total proctocolectomy
- Rectal tumors with indication for upfront surgery or neoadjuvant chemoradiotherapy
- Written informed consent signed before any study procedure
- Age between 18 and 75 years
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Unit of Surgical Oncology - Fondazione del Piemonte per l'Oncologia- IRCCS Istituto di Candiolo, Candiolo, Turin 10060 Coordinator of this site? Confirm its status | Candiolo | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.